Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

- Anti-CD39 monoclonal antibody IPH5201 advances to Phase 2 study in lung cancer
- Innate to receive $5M milestone payment from AstraZeneca
https://finance.yahoo.com/news/innate-pharma-announces-iph5201-phase-050000097.html